Global and Japan Radiopharmaceuticals in Nuclear Medicine Market Insights, Forecast to 2026

1 Study Coverage

• 1.1 Radiopharmaceuticals in Nuclear Medicine Product Introduction
• 1.2 Market Segments
• 1.3 Key Radiopharmaceuticals in Nuclear Medicine Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Type
  • 1.4.2 Diagnostic Radiopharmaceuticals
  • 1.4.3 Therapy Radiopharmaceuticals
  • 1.4.4 Enriched Stable Isotopes
• 1.5 Market by Application
  • 1.5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Application
  • 1.5.2 Diagnostic Application
  • 1.5.3 Therapeutic Application
  • 1.5.4 Research
  • 1.5.5 Pharmaceutical
  • 1.5.6 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size, Estimates and Forecasts
  • 2.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue 2015-2026
  • 2.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales 2015-2026
• 2.2 Global Radiopharmaceuticals in Nuclear Medicine, Market Size by Producing Regions: 2015 VS 2020 VS 2026
• 2.3 Radiopharmaceuticals in Nuclear Medicine Historical Market Size by Region (2015-2020)
  • 2.3.1 Global Radiopharmaceuticals in Nuclear Medicine Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.3.2 Global Radiopharmaceuticals in Nuclear Medicine Retrospective Market Scenario in Revenue by Region: 2015-2020
• 2.4 Radiopharmaceuticals in Nuclear Medicine Market Estimates and Projections by Region (2021-2026)
  • 2.4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Region (2021-2026)
  • 2.4.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Region (2021-2026)

3 Global Radiopharmaceuticals in Nuclear Medicine Competitor Landscape by Players

• 3.1 Global Top Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers
  • 3.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2015-2020)
  • 3.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2015-2020)
• 3.2 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers by Revenue
  • 3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (2015-2020)
  • 3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Radiopharmaceuticals in Nuclear Medicine Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Radiopharmaceuticals in Nuclear Medicine Revenue in 2019
  • 3.2.5 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Manufacturers
• 3.4 Global Radiopharmaceuticals in Nuclear Medicine Manufacturing Base Distribution, Product Types
  • 3.4.1 Radiopharmaceuticals in Nuclear Medicine Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Type
  • 3.4.3 Date of International Manufacturers Enter into Radiopharmaceuticals in Nuclear Medicine Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type (2015-2020)
  • 4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2015-2020)
  • 4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2015-2020)
  • 4.1.3 Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Type (2021-2026)
  • 4.2.3 Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application (2015-2020)
  • 5.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2015-2020)
  • 5.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2015-2020)
  • 5.1.3 Radiopharmaceuticals in Nuclear Medicine Price by Application (2015-2020)
• 5.2 Radiopharmaceuticals in Nuclear Medicine Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Price Forecast by Application (2021-2026)

6 Japan by Players, Type and Application

• 6.1 Japan Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2015-2026
  • 6.1.1 Japan Radiopharmaceuticals in Nuclear Medicine Sales YoY Growth 2015-2026
  • 6.1.2 Japan Radiopharmaceuticals in Nuclear Medicine Revenue YoY Growth 2015-2026
  • 6.1.3 Japan Radiopharmaceuticals in Nuclear Medicine Market Share in Global Market 2015-2026
• 6.2 Japan Radiopharmaceuticals in Nuclear Medicine Market Size by Players (International and Local Players)
  • 6.2.1 Japan Top Radiopharmaceuticals in Nuclear Medicine Players by Sales (2015-2020)
  • 6.2.2 Japan Top Radiopharmaceuticals in Nuclear Medicine Players by Revenue (2015-2020)
• 6.3 Japan Radiopharmaceuticals in Nuclear Medicine Historic Market Review by Type (2015-2020)
  • 6.3.1 Japan Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2015-2020)
  • 6.3.2 Japan Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2015-2020)
  • 6.3.3 Japan Radiopharmaceuticals in Nuclear Medicine Price by Type (2015-2020)
• 6.4 Japan Radiopharmaceuticals in Nuclear Medicine Market Estimates and Forecasts by Type (2021-2026)
  • 6.4.1 Japan Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Type (2021-2026)
  • 6.4.2 Japan Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Type (2021-2026)
  • 6.4.3 Japan Radiopharmaceuticals in Nuclear Medicine Price Forecast by Type (2021-2026)
• 6.5 Japan Radiopharmaceuticals in Nuclear Medicine Historic Market Review by Application (2015-2020)
  • 6.5.1 Japan Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2015-2020)
  • 6.5.2 Japan Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2015-2020)
  • 6.5.3 Japan Radiopharmaceuticals in Nuclear Medicine Price by Application (2015-2020)
• 6.6 Japan Radiopharmaceuticals in Nuclear Medicine Market Estimates and Forecasts by Application (2021-2026)
  • 6.6.1 Japan Radiopharmaceuticals in Nuclear Medicine Sales Forecast by Application (2021-2026)
  • 6.6.2 Japan Radiopharmaceuticals in Nuclear Medicine Revenue Forecast by Application (2021-2026)
  • 6.6.3 Japan Radiopharmaceuticals in Nuclear Medicine Price Forecast by Application (2021-2026)

7 North America

• 7.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2015-2026
• 7.2 North America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  • 7.2.1 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2015-2020)
  • 7.2.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2015-2020)
  • 7.2.3 U.S.
  • 7.2.4 Canada

8 Europe

• 8.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2015-2026
• 8.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  • 8.2.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country
  • 8.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country
  • 8.2.3 Germany
  • 8.2.4 France
  • 8.2.5 U.K.
  • 8.2.6 Italy
  • 8.2.7 Russia

9 Asia Pacific

• 9.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2015-2026
• 9.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  • 9.2.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Region (2015-2020)
  • 9.2.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Region
  • 9.2.3 China
  • 9.2.4 Japan
  • 9.2.5 South Korea
  • 9.2.6 India
  • 9.2.7 Australia
  • 9.2.8 Taiwan
  • 9.2.9 Indonesia
  • 9.2.10 Thailand
  • 9.2.11 Malaysia
  • 9.2.12 Philippines
  • 9.2.13 Vietnam

10 Latin America

• 10.1 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2015-2026
• 10.2 Latin America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  • 10.2.1 Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country
  • 10.2.2 Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country
  • 10.2.3 Mexico
  • 10.2.4 Brazil
  • 10.2.5 Argentina

11 Middle East and Africa

• 11.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2015-2026
• 11.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
  • 11.2.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country
  • 11.2.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country
  • 11.2.3 Turkey
  • 11.2.4 Saudi Arabia
  • 11.2.5 U.A.E

12 Company Profiles

• 12.1 Bracco Imaging S.P.A.
  • 12.1.1 Bracco Imaging S.P.A. Corporation Information
  • 12.1.2 Bracco Imaging S.P.A. Description and Business Overview
  • 12.1.3 Bracco Imaging S.P.A. Sales, Revenue and Gross Margin (2015-2020)
  • 12.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.1.5 Bracco Imaging S.P.A. Recent Development
• 12.2 Cambridge Isotope Laboratories, Inc.
  • 12.2.1 Cambridge Isotope Laboratories, Inc. Corporation Information
  • 12.2.2 Cambridge Isotope Laboratories, Inc. Description and Business Overview
  • 12.2.3 Cambridge Isotope Laboratories, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 12.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.2.5 Cambridge Isotope Laboratories, Inc. Recent Development
• 12.3 Cardinal Health, Inc.
  • 12.3.1 Cardinal Health, Inc. Corporation Information
  • 12.3.2 Cardinal Health, Inc. Description and Business Overview
  • 12.3.3 Cardinal Health, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 12.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.3.5 Cardinal Health, Inc. Recent Development
• 12.4 Covidien, Plc
  • 12.4.1 Covidien, Plc Corporation Information
  • 12.4.2 Covidien, Plc Description and Business Overview
  • 12.4.3 Covidien, Plc Sales, Revenue and Gross Margin (2015-2020)
  • 12.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.4.5 Covidien, Plc Recent Development
• 12.5 Eczacibasi-Monrol
  • 12.5.1 Eczacibasi-Monrol Corporation Information
  • 12.5.2 Eczacibasi-Monrol Description and Business Overview
  • 12.5.3 Eczacibasi-Monrol Sales, Revenue and Gross Margin (2015-2020)
  • 12.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.5.5 Eczacibasi-Monrol Recent Development
• 12.6 Fujifilm Holdings Corporation
  • 12.6.1 Fujifilm Holdings Corporation Corporation Information
  • 12.6.2 Fujifilm Holdings Corporation Description and Business Overview
  • 12.6.3 Fujifilm Holdings Corporation Sales, Revenue and Gross Margin (2015-2020)
  • 12.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.6.5 Fujifilm Holdings Corporation Recent Development
• 12.7 GE Healthcare (Subsidiary Of General Electric Company)
  • 12.7.1 GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
  • 12.7.2 GE Healthcare (Subsidiary Of General Electric Company) Description and Business Overview
  • 12.7.3 GE Healthcare (Subsidiary Of General Electric Company) Sales, Revenue and Gross Margin (2015-2020)
  • 12.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Development
• 12.8 IBA Group
  • 12.8.1 IBA Group Corporation Information
  • 12.8.2 IBA Group Description and Business Overview
  • 12.8.3 IBA Group Sales, Revenue and Gross Margin (2015-2020)
  • 12.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.8.5 IBA Group Recent Development
• 12.9 Isotec, Inc. (Sigma-Aldrich)
  • 12.9.1 Isotec, Inc. (Sigma-Aldrich) Corporation Information
  • 12.9.2 Isotec, Inc. (Sigma-Aldrich) Description and Business Overview
  • 12.9.3 Isotec, Inc. (Sigma-Aldrich) Sales, Revenue and Gross Margin (2015-2020)
  • 12.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Development
• 12.10 Lantheus Medical Imaging, Inc.
  • 12.10.1 Lantheus Medical Imaging, Inc. Corporation Information
  • 12.10.2 Lantheus Medical Imaging, Inc. Description and Business Overview
  • 12.10.3 Lantheus Medical Imaging, Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 12.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.10.5 Lantheus Medical Imaging, Inc. Recent Development
• 12.11 Bracco Imaging S.P.A.
  • 12.11.1 Bracco Imaging S.P.A. Corporation Information
  • 12.11.2 Bracco Imaging S.P.A. Description and Business Overview
  • 12.11.3 Bracco Imaging S.P.A. Sales, Revenue and Gross Margin (2015-2020)
  • 12.11.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Products Offered
  • 12.11.5 Bracco Imaging S.P.A. Recent Development
• 12.12 Ntp Radioisotopes (Pty), Ltd.
  • 12.12.1 Ntp Radioisotopes (Pty), Ltd. Corporation Information
  • 12.12.2 Ntp Radioisotopes (Pty), Ltd. Description and Business Overview
  • 12.12.3 Ntp Radioisotopes (Pty), Ltd. Sales, Revenue and Gross Margin (2015-2020)
  • 12.12.4 Ntp Radioisotopes (Pty), Ltd. Products Offered
  • 12.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Development
• 12.13 Siemens Healthcare (Subsidiary Of Siemens AG)
  • 12.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
  • 12.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Description and Business Overview
  • 12.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Sales, Revenue and Gross Margin (2015-2020)
  • 12.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Products Offered
  • 12.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Development
• 12.14 Taiyo Nippon Sanso Corporation
  • 12.14.1 Taiyo Nippon Sanso Corporation Corporation Information
  • 12.14.2 Taiyo Nippon Sanso Corporation Description and Business Overview
  • 12.14.3 Taiyo Nippon Sanso Corporation Sales, Revenue and Gross Margin (2015-2020)
  • 12.14.4 Taiyo Nippon Sanso Corporation Products Offered
  • 12.14.5 Taiyo Nippon Sanso Corporation Recent Development
• 12.15 Urenco Limited
  • 12.15.1 Urenco Limited Corporation Information
  • 12.15.2 Urenco Limited Description and Business Overview
  • 12.15.3 Urenco Limited Sales, Revenue and Gross Margin (2015-2020)
  • 12.15.4 Urenco Limited Products Offered
  • 12.15.5 Urenco Limited Recent Development
• 12.16 Rotem Industries, Ltd., Inc.
  • 12.16.1 Rotem Industries, Ltd., Inc. Corporation Information
  • 12.16.2 Rotem Industries, Ltd., Inc. Description and Business Overview
  • 12.16.3 Rotem Industries, Ltd., Inc. Sales, Revenue and Gross Margin (2015-2020)
  • 12.16.4 Rotem Industries, Ltd., Inc. Products Offered
  • 12.16.5 Rotem Industries, Ltd., Inc. Recent Development
• 12.17 Australian Nuclear Association And Technology Organization (ANSTO)
  • 12.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
  • 12.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Description and Business Overview
  • 12.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Sales, Revenue and Gross Margin (2015-2020)
  • 12.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Products Offered
  • 12.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Development
• 12.18 Board of Radiation And Isotope Technology (BRIT)
  • 12.18.1 Board of Radiation And Isotope Technology (BRIT) Corporation Information
  • 12.18.2 Board of Radiation And Isotope Technology (BRIT) Description and Business Overview
  • 12.18.3 Board of Radiation And Isotope Technology (BRIT) Sales, Revenue and Gross Margin (2015-2020)
  • 12.18.4 Board of Radiation And Isotope Technology (BRIT) Products Offered
  • 12.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Development
• 12.19 Institute of Atomic Energy Polatom Radioisotope Centre
  • 12.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
  • 12.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Description and Business Overview
  • 12.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Sales, Revenue and Gross Margin (2015-2020)
  • 12.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Products Offered
  • 12.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Development
• 12.20 Institute of Isotopes Co., Ltd.
  • 12.20.1 Institute of Isotopes Co., Ltd. Corporation Information
  • 12.20.2 Institute of Isotopes Co., Ltd. Description and Business Overview
  • 12.20.3 Institute of Isotopes Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
  • 12.20.4 Institute of Isotopes Co., Ltd. Products Offered
  • 12.20.5 Institute of Isotopes Co., Ltd. Recent Development
• 12.21 Institute Of Radioelement (IRE)
  • 12.21.1 Institute Of Radioelement (IRE) Corporation Information
  • 12.21.2 Institute Of Radioelement (IRE) Description and Business Overview
  • 12.21.3 Institute Of Radioelement (IRE) Sales, Revenue and Gross Margin (2015-2020)
  • 12.21.4 Institute Of Radioelement (IRE) Products Offered
  • 12.21.5 Institute Of Radioelement (IRE) Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter’s Five Forces Analysis
• 13.5 Primary Interviews with Key Radiopharmaceuticals in Nuclear Medicine Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Radiopharmaceuticals in Nuclear Medicine Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details